Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk shares dropped sharply on Wednesday after the Danish pharmaceutical giant flagged a potential 13% decline in sales and profit for 2026, marking a notable reversal for the company behind weight-loss drug Wegovy and diabetes treatment Ozempic. Early trading in Copenhagen saw shares plunge 18%, according to the Financial Times. https://www.ft.com/content/d148ce25-fa76-468b-b9ac-95c62a994a55
Standard Chartered share price climbs ahead of BoE as STAN.L hovers near 52-week high

Standard Chartered share price climbs ahead of BoE as STAN.L hovers near 52-week high

Standard Chartered shares climbed on Wednesday, holding near the upper end of their recent range as investors weighed central bank risks against a weak mood in European stocks. Around 09:05 GMT, the stock was up roughly 1.2% at 1,901.5 pence, after closing at 1,879.0 pence the day before. Trading during the session fluctuated between 1,888.5 and 1,910.0 pence.
4 February 2026
GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK is projecting slower sales growth in 2026 under new CEO Luke Miels, who took over from Emma Walmsley earlier this year. The company is bracing for patent expiries on its leading HIV drugs starting in 2028. It now expects revenue growth of 3% to 5% at constant currency, while warning that vaccines and general medicines sales might decline. Shares climbed 1.4% by 0809 GMT after an initial drop. Core earnings per share for Q4 came in at 25.5 pence, supported by an 8% sales increase to £8.62 billion.
4 February 2026
1 101 102 103 104 105 608

Google Preferred Source